Open AccessThe effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: An observational study
Author(s) -
Wolfgang Kruis,
Ludger Leifeld,
J Morgenstern,
Roland H. Pfützer,
Birgitta Reimers,
Sabine Ceplis-Kastner
Publication year - 2012
Publication title -
journal of crohn s and colitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.277
H-Index - 80
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1016/j.crohns.2012.07.004
Subject(s) - mesalazine , medicine , ulcerative colitis , dosing , observational study , medical prescription , clinical trial , randomized controlled trial , pharmacology , disease
The optimal mesalazine dosing strategy for ulcerative colitis (UC) continues to evolve. The current study aimed to explore whether documenting drug use could prompt changes in prescribing habits.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom